Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%

JAMA Ophthalmology

Volumn 132, Issue 2, 2014, Pages 150-154

  Schoenberger, Scott D ^a   Kim, Stephen J ^a   Sheng, Jinsong ^a   Calcutt, M Wade ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; EPIRETINAL MEMBRANE; HUMANS; IMMUNOENZYME TECHNIQUES; KETOROLAC TROMETHAMINE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL PERFORATIONS; TANDEM MASS SPECTROMETRY; VITRECTOMY; VITREOUS BODY;

EID: 84894271457     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.5692     Document Type: Article

References (27)

1. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55(2):108-133.
2. Schoenberger SD, Kim SJ. Nonsteroidal anti-inflammatory drugs for retinal disease. Int J Inflam. 2013;2013:281981.
3. Kim SJ, Doherty TJ, Cherney EF. Intravitreal ketorolac for chronic uveitis and macular edema: a pilot study. Arch Ophthalmol. 2012;130(4): 456-460.
4. Patel M, Chan CC. Immunopathological aspects of age-related macular degeneration. Semin Immunopathol. 2008;30(2):97-110.
5. Schoenberger SD, Kim SJ, Sheng J, Rezaei KA, LalezaryM, Cherney E. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Invest Ophthalmol Vis Sci. 2012;53(9):5906-5911.
6. Reddy R, Kim SJ. Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery. Clin Ophthalmol. 2011;5:751-758.
7. Rezaei KA, Toma HS, Cai J, Penn JS, Sternberg P, Kim SJ. Reduced choroidal neovascular membrane formation in cyclooxygenase-2 nullmice. Invest Ophthalmol Vis Sci. 2011;52(2):701-707.
8. Barañano DE, Kim SJ, Edelhauser HF, Durairaj C, Kompella UB, Handa JT. Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. Br J Ophthalmol. 2009;93(10):1387-1390.
9. ChinMS, Nagineni CN, Hooper LC, Detrick B, Hooks JJ. Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42(10):2338-2346.
10. Shinomiya S, Naraba H, Ueno A, et al. Regulation of TNFα and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem Pharmacol. 2001;61(9):1153-1160.
11. Monnier Y, Zaric J, Rüegg C. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy. 2005;4(1):31-38.
12. Yanni SE, Barnett JM, ClarkML, Penn JS. The role of PGE2 receptor EP4 in pathologic ocular angiogenesis. Invest Ophthalmol Vis Sci. 2009;50(11):5479- 5486.
13. Maloney SC, Fernandes BF, Castiglione E, et al. Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients. Retina. 2009;29(2): 176-180.
14. Kim SJ, Toma HS. Inhibition of choroidal neovascularization by intravitreal ketorolac. Arch Ophthalmol. 2010;128(5):596-600.
15. Cheng T, CaoW,Wen R, Steinberg RH, LaVail MM. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells. Invest Ophthalmol Vis Sci. 1998;39(3):581-591.
16. Johnson EI, Dunlop ME, Larkins RG. Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature. Curr Eye Res. 1999;18(2):79-82.
17. Kern TS, Miller CM, Du Y, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes. 2007;56(2):373-379.
18. Amrite AC, Ayalasomayajula SP, Cheruvu NPS, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 2006;47(3):1149-1160.
19. Flaxel C, Schain MB, Hamon SC, Francis PJ. Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study. Retina. 2012;32(3):417-423.
20. Gomi F, Sawa M, TsujikawaM, Nishida K. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina. 2012;32(9):1804-1810.
21. The DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: a multicenter randomized controlled clinical trial. Diabetes. 1989;38(4):491-498.
22. Hattori Y, Hashizume K, Nakajima K, Nishimura Y, NakaM,Miyanaga K. The effect of long-term treatment with sulindac on the progression of diabetic retinopathy. Curr Med Res Opin. 2007;23(8):1913-1917.
23. Chew EY, Kim J, Coleman HR, et al. Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema. Retina. 2010;30(3):459-467.
24. Heier JS, Awh CC, Busbee BG, et al. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Retina. 2009;29(9):1310-1313.
25. Attar M, Schiffman R, Borbridge L, Farnes Q, Welty D. Ocular pharmacokinetics of 0.45% ketorolac tromethamine. Clin Ophthalmol. 2010;4:1403-1408.
26. Bucci FA Jr,Waterbury LD. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification. Adv Ther. 2011;28(12):1089-1095.
27. Kent AR, King L, Bartholomew LR. Vitreous concentration of topically applied brimonidine-purite 0.15%. J Ocul Pharmacol Ther. 2006;22(4):242-246.